/
DCF Valuation
Base-case fair value
$61.71
Intrinsic $82.28 · 25% MOS
Current price: $54.00
Base-case summary
Our base-case DCF for Bristol Myers Squibb Co (BMY) projects 10 years of free cash flow growth at 2.0% for years 1–5 and 1.0% for years 6–10, anchored to a default 8% growth assumption, then applies a 2.5% perpetual growth rate and a 8.0% discount rate. Starting from $11.9B in trailing free cash flow, this produces an intrinsic value of $82.28 per share. A 25% safety margin gives a fair value of $61.71, suggesting the stock is currently 14% undervalued against the $54.00 market price.
See 3 scenarios side by side
Conservative, Base, and Optimistic fair values, plus the sensitivity matrix and FCF history. Free account.
Model inputs
TTM Free Cash Flow
$11.9B
Cash & equivalents
$10.5B
Total debt
$48.4B
Shares outstanding
2.0B